|
Acrostic - facilitating, supporting and documenting read-across!
|
|
4
|
497
|
April 8, 2024
|
|
N-Nitroso Edoxaban Desmethyl Impurity CPCA Score
|
|
6
|
652
|
April 8, 2024
|
|
Claryfying the photo-toxicity of NDEA and colleagues: the link for elucidation of the skin cancers pathogenesis
|
|
0
|
115
|
April 6, 2024
|
|
Nitrosamine Impurity Test Market expected to grow exponentially by 2029
|
|
0
|
465
|
November 19, 2023
|
|
Theoretical estimation of the conversion of a tertiary amine to nitrosamine
|
|
8
|
776
|
April 6, 2024
|
|
👨💻 Quantitation of MNP & CPNP in Rifampin and Rifapentine by LC-MS/MS
|
|
0
|
274
|
April 5, 2024
|
|
📅 Ascorbic Acid And Alpha-Tocopherol As Nitrite Scavengers - An Elegant And Simple Solution To Mitigate Nitrosamines In Drug Products -Event
|
|
0
|
564
|
April 5, 2024
|
|
Overlapping gene/mutation patterns between changes induced in p53 and RAS oncogenes by some nitrosamines with those induced within photocarcinogenesis: a good start to unravel the puzzle?
|
|
2
|
108
|
April 5, 2024
|
|
Request for risk assessment and confirmatory testing for nortriptyline containing products
|
|
4
|
426
|
April 3, 2024
|
|
AI Limit for Nitroso Nebivolol
|
|
11
|
2043
|
April 3, 2024
|
|
EMA - Update Appendix 3: Enhanced Ames Test conditions for N-nitrosamines
|
|
8
|
922
|
April 2, 2024
|
|
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day
|
|
26
|
3558
|
April 2, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
82
|
8065
|
April 1, 2024
|
|
1st release of Lhasa 'Complex Nitrosamines' data sharing initiative
|
|
6
|
963
|
March 31, 2024
|
|
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub
|
|
1
|
776
|
February 6, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
455
|
March 28, 2024
|
|
Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs) -Pub
|
|
17
|
2084
|
March 28, 2024
|
|
🇨🇦 Health Canada updated the guidance and Appendix 1(March 15, 2024)
|
|
10
|
1625
|
March 27, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
5
|
663
|
March 25, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
631
|
March 22, 2024
|
|
N-Nitrosamine impurity of heterocyclic aromatic ring
|
|
16
|
2655
|
March 22, 2024
|
|
IVACAFTOR (N-Nitroso Ivacaftor)
|
|
0
|
255
|
March 22, 2024
|
|
Nitrosamines in Bacon: a Case Study of Balancing Risks
|
|
1
|
217
|
March 20, 2024
|
|
Nitroso amines quantification in drugs which are having MDD Value more than 10.0g/Day
|
|
2
|
261
|
March 20, 2024
|
|
Calculating Nitrosamine Limits (MasterClass)
|
|
4
|
1683
|
March 19, 2024
|
|
N-nitroso cyclamate
|
|
9
|
412
|
March 15, 2024
|
|
Application of duplex sequencing to evaluate mutagenicity -Pub
|
|
1
|
230
|
March 14, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
368
|
March 13, 2024
|
|
NDMA evaluation in battery of in vivo Genotoxicity assays once again leading to AI much greater than 96 ng/day
|
|
0
|
186
|
March 13, 2024
|
|
USP User Forum in 🇨🇦 Toronto
|
|
0
|
146
|
March 12, 2024
|